Abiraterone in the treatment of metastatic castration-resistant prostate cancer

References

• ScherHISawyersCLBiology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axisJ Clin Oncol200523328253826116278481
   PubMed Web of Science ®Google Scholar
• GellerJLiuJAlbertJFayWBerryCCWeisPRelationship between human prostatic epithelial cell protein synthesis and tissue dihydrotestosterone levelClin Endocrinol (Oxf)19872621551613665114
   PubMed Web of Science ®Google Scholar
• MohlerJLGregoryCWFordOH3rdThe androgen axis in recurrent prostate cancerClin Cancer Res200410244044814760063
   PubMed Web of Science ®Google Scholar
• NishiyamaTHashimotoYTakahashiKThe influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancerClin Cancer Res200410217121712615534082
   PubMed Web of Science ®Google Scholar
• PageSTLinDWMostaghelEAPersistent intraprostatic androgen concentrations after medical castration in healthy menJ Clin Endocrinol Metab200691103850385616882745
   PubMed Web of Science ®Google Scholar
• MontgomeryRBMostaghelEAVessellaRMaintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growthCancer Res200868114447445418519708
   PubMed Web of Science ®Google Scholar
• CuligZHoffmannJErdelMSwitch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model systemBr J Cancer199981224225110496349
   PubMed Web of Science ®Google Scholar
• GregoryCWJohnsonRTJrMohlerJLFrenchFSWilsonEMAndrogen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgenCancer Res20016172892289811306464
   PubMed Web of Science ®Google Scholar
• GregoryCWHamilKGKimDAndrogen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genesCancer Res19985824571857249865729
   PubMed Web of Science ®Google Scholar
• MohlerJLMorrisTLFordOH3rdAlveyRFSakamotoCGregoryCWIdentification of differentially expressed genes associated with androgen-independent growth of prostate cancerProstate200251424725511987153
   PubMed Web of Science ®Google Scholar
• ScherHIBuchananGGeraldWButlerLMTilleyWDTargeting the androgen receptor: improving outcomes for castration-resistant prostate cancerEndocr Relat Cancer200411345947615369448
   PubMed Web of Science ®Google Scholar
• LabrieFBelangerASimardJLuu-TheVLabrieCDHEA and peripheral androgen and estrogen formation: intracinologyAnn N Y Acad Sci199577416288597456
   PubMed Web of Science ®Google Scholar
• LockeJAWasanKMNelsonCCGunsESLeonCGAndrogen-mediated cholesterol metabolism in LNCaP and PC-3 cell lines is regulated through two different isoforms of acyl-coenzyme A: cholesterol acyltransferase (ACAT)Prostate2008681203318000807
   PubMed Web of Science ®Google Scholar
• LockeJAGunsESLubikAAAndrogen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancerCancer Res200868156407641518676866
   PubMed Web of Science ®Google Scholar
• LeonCGLockeJAAdomatHHAlterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft modelProstate201070439040019866465
   PubMed Web of Science ®Google Scholar
• MostaghelEASolomonKRPeltonKFreemanMRMontgomeryRBImpact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumorsPLoS One201271e3006222279565
   PubMed Web of Science ®Google Scholar
• StanbroughMBubleyGJRossKIncreased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancerCancer Res20066652815282516510604
   PubMed Web of Science ®Google Scholar
• HoflandJvan WeerdenWMDitsNFEvidence of limited contributions for intratumoral steroidogenesis in prostate cancerCancer Res20107031256126420086173
   PubMed Web of Science ®Google Scholar
• BubendorfLKononenJKoivistoPSurvey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarraysCancer Res199959480380610029066
   PubMed Web of Science ®Google Scholar
• FordOH3rdGregoryCWKimDSmithermanABMohlerJLAndrogen receptor gene amplification and protein expression in recurrent prostate cancerJ Urol200317051817182114532783
   PubMed Web of Science ®Google Scholar
• LinjaMJSavinainenKJSaramakiORTammelaTLJVessellaRLVisakorpiTAmplification and overexpression of androgen receptor gene in hormone-refractory prostate cancerCancer Res20016193550355511325816
   PubMed Web of Science ®Google Scholar
• VisakorpiTHyytinenEKoivistoPIn vivo amplification of the androgen receptor gene and progression of human prostate cancerNat Genet1995944014067795646
   PubMed Web of Science ®Google Scholar
• van der KwastTHSchalkenJRuizeveld de WinterJAAndrogen receptors in endocrine-therapy-resistant human prostate cancerInt J Cancer19914821891931708363
   PubMed Web of Science ®Google Scholar
• Ruizeveld de WinterJAJanssenPJSleddensHMAndrogen receptor status in localized and locally progressive hormone refractory human prostate cancerAm J Pathol199414447357467512791
   PubMed Web of Science ®Google Scholar
• TaplinMEBubleyGJShusterTDMutation of the androgen-receptor gene in metastatic androgen-independent prostate cancerN Engl J Med199533221139313987723794
   PubMed Web of Science ®Google Scholar
• HolzbeierleinJLalPLaTulippeEGene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistanceAm J Pathol2004164121722714695335
   PubMed Web of Science ®Google Scholar
• LatilABiecheIVidaudDEvaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assaysCancer Res20016151919192611280747
   PubMed Web of Science ®Google Scholar
• MiyamotoHRahmanMMChangCMolecular basis for the antiandrogen withdrawal syndromeJ Cell Biochem200491131214689576
   PubMed Web of Science ®Google Scholar
• ChenCDWelsbieDSTranCMolecular determinants of resistance to antiandrogen therapyNat Med2004101333914702632
   PubMed Web of Science ®Google Scholar
• BrookeGNBevanCLThe role of androgen receptor mutations in prostate cancer progressionCurr Genomics2009101182519721807
   PubMed Web of Science ®Google Scholar
• CuligZHobischACronauerMVMutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesteroneMol Endocrinol1993712154115508145761
   PubMed Web of Science ®Google Scholar
• TanJShariefYHamilKGDehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cellsMol Endocrinol19971144504599092797
   PubMed Web of Science ®Google Scholar
• TaplinMEDrug insight: role of the androgen receptor in the development and progression of prostate cancerNat Clin Pract Oncol20074423624417392714
   PubMedGoogle Scholar
• YuanXBalkSPMechanisms mediating androgen receptor reactivation after castrationUrol Oncol2009271364119111796
   PubMed Web of Science ®Google Scholar
• ZhaoXYMalloyPJKrishnanAVGlucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptorNat Med20006670370610835690
   PubMed Web of Science ®Google Scholar
• SteinkampMPO’MahonyOABrogleyMTreatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapyCancer Res200969104434444219366804
   PubMed Web of Science ®Google Scholar
• KorpalMKornJMGaoXAn F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide)Cancer Discov2013391030104323842682
   PubMed Web of Science ®Google Scholar
• BalbasMDEvansMJHosfieldDJOvercoming mutation-based resistance to antiandrogens with rational drug designElife20132e0049923580326
   PubMed Web of Science ®Google Scholar
• JosephJDLuNQianJA clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509Cancer Discov2013391020102923779130
   PubMed Web of Science ®Google Scholar
• GuoZYangXSunFA novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growthCancer Res20096962305231319244107
   PubMed Web of Science ®Google Scholar
• HuRDunnTAWeiSLigand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancerCancer Res2009691162219117982
   PubMed Web of Science ®Google Scholar
• ZhaoJJLinJLwinTmicroRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphomaBlood2010115132630263920086245
   PubMed Web of Science ®Google Scholar
• HornbergEYlitaloEBCrnalicSExpression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survivalPLoS One201164e1905921552559
   PubMed Web of Science ®Google Scholar
• HaileSSadarMDAndrogen receptor and its splice variants in prostate cancerCell Mol Life Sci201168243971398121748469
   PubMed Web of Science ®Google Scholar
• GreenbergEEndocrine therapy in the management of prostatic cancerClin Endocrinol Metab1980923693816994946
   PubMedGoogle Scholar
• RobinsonMRShearerRJFergussonJDAdrenal suppression in the treatment of carcinoma of the prostateBr J Urol19744655555594422260
   PubMedGoogle Scholar
• SamsonDJSeidenfeldJSchmittBSystematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinomaCancer200295236137612124837
   PubMed Web of Science ®Google Scholar
• SchmittBBennettCSeidenfeldJSamsonDWiltTMaximal androgen blockade for advanced prostate cancer [review]Cochrane Database Syst Rev20002CD00152610796804
   PubMedGoogle Scholar
• CaubetJFTostesonTDDongEWMaximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogensUrology199749171789000189
   PubMed Web of Science ®Google Scholar
• SmallEJRyanCJThe case for secondary hormonal therapies in the chemotherapy ageJ Urol20061766 Pt 2S66S7117084172
   PubMed Web of Science ®Google Scholar
• de BonoJSLogothetisCJFizaziKAbiraterone acetate (AA) plus low dose prednisone (P) improves overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after docetaxel-based chemotherapy (chemo): results of COU-AA-301, a randomized double-blind placebo-controlled Phase III study [abstract]Ann Oncol201021Suppl 8LBA5
   Google Scholar
• ScherHIBeerTMHiganoCSAntitumour activity of MDV3100 in castration-resistant prostate cancer: a Phase I–II studyLancet201037597241437144620398925
   PubMed Web of Science ®Google Scholar
• EfstathiouETitusMTsavachidouDEffects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in boneJ Clin Oncol201230663764322184395
   PubMed Web of Science ®Google Scholar
• HandrattaVDVasaitisTSNjarVCNovel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft modelJ Med Chem20054882972298415828836
   PubMed Web of Science ®Google Scholar
• RowlandsMGBarrieSEChanFEsters of 3-pyridylacetic acid that combine potent inhibition of 17 alpha-hydroxylase/C17,20-lyase (cytochrome P45017 alpha) with resistance to esterase hydrolysisJ Med Chem19953821419141977473546
   PubMed Web of Science ®Google Scholar
• AttardGReidAHAuchusRJClinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancerJ Clin Endocrinol Metab201297250751622170708
   PubMed Web of Science ®Google Scholar
• RichardsJLimACHayCWInteractions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100Cancer Res20127292176218222411952
   PubMed Web of Science ®Google Scholar
• SoiferHSSouleimanianNWuSDirect regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cellsJ Biol Chem201228763777378722174412
   PubMed Web of Science ®Google Scholar
• EilCKetoconazole binds to the human androgen receptorHorm Metab Res19922483673701526623
   PubMed Web of Science ®Google Scholar
• LiREvaulKSharmaKKAbiraterone inhibits 3β-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancerClin Cancer Res201218133571357922753664
   PubMed Web of Science ®Google Scholar
• BarrieSEPotterGAGoddardPMHaynesBPDowsettMJarmanMPharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17–20 lyase)J Steroid Biochem Mol Biol1994505–62672737918112
   PubMed Web of Science ®Google Scholar
• O’DonnellAJudsonIDowsettMHormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancerBr J Cancer200490122317232515150570
   PubMed Web of Science ®Google Scholar
• AttardGReidAHYapTAPhase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone drivenJ Clin Oncol200826284563457118645193
   PubMed Web of Science ®Google Scholar
• RyanCJSmithMRFongLPhase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapyJ Clin Oncol20102891481148820159824
   PubMed Web of Science ®Google Scholar
• ToddMMeyersMLCharnasRAcharyaMMolinaAFast and flawed or scientifically sound: the argument for administering oral oncology drugs during fastingJ Clin Oncol201230888888922331950
   PubMed Web of Science ®Google Scholar
• Janssen-Ortho Inc., CanadaA Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer Available from: http://clinicaltrials.gov/show/NCT01424930. NLM identifier: NCT01424930Accessed December 10, 2013
   Google Scholar
• University of ChicagoFood Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer Available from: http://clinicaltrials.gov/show/NCT01543776. NLM identifier: NCT01543776Accessed December 10, 2013
   Google Scholar
• RatainMJFlushing oral oncology drugs down the toiletJ Clin Oncol201129303958395921931020
   PubMed Web of Science ®Google Scholar
• MarburyTStonerockRTranNGonzalezMA Phase I single dose open-label reduced/staged pharmacokinetic (PK) and safety study of abiraterone acetate (AA) in men with imapired renal functionEur J Cancer201147Suppl 1S502
   Web of Science ®Google Scholar
• AcharyaMGonzalezMMannensGA Phase I, open-label, single-dose, mass balance study of 14C-labeled abiraterone acetate in healthy male subjectsXenobiotica201343437938923020788
   PubMed Web of Science ®Google Scholar
• RyanCJHalabiSOuSSVogelzangNJKantoffPSmallEJAdrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B studyClin Cancer Res20071372030203717404083
   PubMed Web of Science ®Google Scholar
• AttardGReidAHA’HernRSelective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancerJ Clin Oncol200927233742374819470933
   PubMed Web of Science ®Google Scholar
• RyanCJShahSEfstathiouEPhase II study of abiraterone acetate in chemotherapy-naïve metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic responseClin Cancer Res201117144854486121632851
   PubMed Web of Science ®Google Scholar
• ReidAHAttardGDanilaDCSignificant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetateJ Clin Oncol20102891489149520159823
   PubMed Web of Science ®Google Scholar
• DanilaDCMorrisMJde BonoJSPhase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancerJ Clin Oncol20102891496150120159814
   PubMed Web of Science ®Google Scholar
• FizaziKScherHIMolinaAAbiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled Phase III studyLancet Oncol2012131098399222995653
   PubMed Web of Science ®Google Scholar
• GoodmanOBFlaigTWMolinaAExploratory analysis of the visceral disease (VD) patient subset in COU-AA-301, a Phase III study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) [abstract]J Clin Oncol201331Suppl 61423045578
   PubMed Web of Science ®Google Scholar
• SternbergCNMolinaANorthSEffect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapyAnn Oncol20132441017102523152362
   PubMed Web of Science ®Google Scholar
• LogothetisCJBaschEMolinaAEffect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trialLancet Oncol201213121210121723142059
   PubMed Web of Science ®Google Scholar
• RyanCJSmithMRde BonoJSAbiraterone in metastatic prostate cancer without previous chemotherapyN Engl J Med2013368213814823228172
   PubMed Web of Science ®Google Scholar
• RathkopfDESmithMRDe BonoJSUpdated interim analysis (IA) of COU-AA-302, a randomized Phase III study of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy [abstract]J Clin Oncol201331Suppl 6523169505
   PubMed Web of Science ®Google Scholar
• FerraldeschiRSharifiNAuchusRJAttardGMolecular pathways: inhibiting steroid biosynthesis in prostate cancerClin Cancer Res201319133353335923470964
   PubMed Web of Science ®Google Scholar
• PiaAVignaniFAttardGStrategies for managing ACTH dependent mineralocorticoid excess induced by abirateroneCancer Treat Rev201339896697323582279
   PubMed Web of Science ®Google Scholar
• ProcopioGGrassiPTestaISafety of abiraterone acetate in castration-resistant prostate cancer patients with concomitant cardiovascular risk factorsAm J Clin OncolEpub 9212013
   Google Scholar
• TolcherAWChiKNShoreNDEffect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancerCancer Chemother Pharmacol201270230531322752297
   PubMed Web of Science ®Google Scholar
• ChiKNTolcherALeePEffect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancerCancer Chemother Pharmacol201371123724423064959
   PubMed Web of Science ®Google Scholar
• BertilssonLDahlMLDalenPAl-ShurbajiAMolecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugsBr J Clin Pharmacol200253211112211851634
   PubMed Web of Science ®Google Scholar
• JanssenResearchDevelopmentLLCA Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Abiraterone in Healthy Male Participants Available from: http://clinicaltrials.gov/show/NCT01655147. NLM identifier: NCT01655147Accessed December 10, 2013
   Google Scholar
• JanssenResearchDevelopmentLLCA Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Abiraterone Following Administration of Abiraterone Acetate Tablets in Healthy Adult Men Available from: http://clinicaltrials.gov/show/NCT01588782. NLM identifier: NCT01588782Accessed December 10, 2013
   Google Scholar
• DendreonConcurrent Versus Sequential Treatment With Sipuleucel-T and Abiraterone in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC) Available from: http://clinicaltrials.gov/show/NCT01487863. NLM identifier: NCT01487863Accessed December 10, 2013
   Google Scholar
• FitzpatrickJMde WitRTaxane mechanisms of action: potential implications for treatment sequencing in metastatic castration-resistant prostate cancerEur UrolEpub 7252013
   Google Scholar
• GanLChenSWangYInhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancerCancer Res200969218386839419826044
   PubMed Web of Science ®Google Scholar
• LoriotYBianchiniDIleanaEAntitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)Ann Oncol20132471807181223576708
   PubMed Web of Science ®Google Scholar
• SchraderAJBoegemannMOhlmannCHEnzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abirateroneEur Urol2014651303623849416
   PubMed Web of Science ®Google Scholar
• Janssen Pharmaceutica N.V., BelgiumAbiraterone With Different Steroid Regimens for Side Effect Related to Mineralcorticoid Excess Prevention in Prostate Cancer Prior to Chemotherapy Available from: http://clinicaltrials.gov/show/NCT01867710. NLM identifier:NCT01867710Accessed December 10, 2013
   Google Scholar
• DarshanMSLoftusMSThadani-MuleroMTaxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancerCancer Res201171186019602921799031
   PubMed Web of Science ®Google Scholar
• ZhuMLHorbinskiCMGarzottoMQianDZBeerTMKyprianouNTubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancerCancer Res201070207992800220807808
   PubMed Web of Science ®Google Scholar
• HuillardOAlbigesLEymardJCEfficacy of docetaxel chemotherapy in metastatic prostate cancer (mPC) patients (pts) experiencing early castration resistance (CR) [abstract]J Clin Oncol201331Suppl5075
   Google Scholar
• MezynskiJPezaroCBianchiniDAntitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?Ann Oncol201223112943294722771826
   PubMed Web of Science ®Google Scholar
• AngelerguesAMailletDFlechonAPrognostic factors of survival in patients with metastatic castration resistant prostate cancer (mCRPC) treated with cabazitaxel: sequencing might matter [abstract]J Clin Oncol201331Suppl5063
   Google Scholar
• MostaghelEAMarckBTPlymateSRResistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variantsClin Cancer Res201117185913592521807635
   PubMed Web of Science ®Google Scholar
• CaiCChenSNgPIntratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitorsCancer Res201171206503651321868758
   PubMed Web of Science ®Google Scholar
• MostaghelEAPageSTLinDWIntraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancerCancer Res200767105033504117510436
   PubMed Web of Science ®Google Scholar
• CaffoOPalermoAVecciaABiochemical and objective response to abiraterone acetate withdrawal: incidence and clinical relevance of a new scenario for castration-resistant prostate cancerUrology20138251090109324001702
   PubMed Web of Science ®Google Scholar
• GauthierHBousquetGPouesselDCulineSAbiraterone acetate withdrawal syndrome: does it exist?Case Rep Oncol20125238538723525261
   PubMedGoogle Scholar
• WitjesJAA case of abiraterone acetate withdrawalEur Urol201364351751823806520
   PubMed Web of Science ®Google Scholar
• LabrieFDupontABelangerANew approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgensProstate1983465795946415630
   PubMed Web of Science ®Google Scholar
• SahuBLaaksoMPihlajamaaPFoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cellsCancer Res20137351570158023269278
   PubMed Web of Science ®Google Scholar
• University of WashingtonAbiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Available from: http://clinicaltrials.gov/show/NCT01508234. NLM identifier: NCT01503229Accessed December 10, 2013
   Google Scholar
• Terence FriedlanderMDA Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer Available from: http://clinicaltrials.gov/show/NCT01637402. NLM identifier: NCT01637402Accessed December 10, 2013
   Google Scholar
• Astellas Pharma Global Development, IncA Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients Available from: http://clinicaltrials.gov/show/NCT01650194. NLM identifier: NCT01650194Accessed December 10, 2013
   Google Scholar
• Alliance for Clinical Trials in OncologyEnzalutamide With or Without Abiraterone Acetate and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer Available from: http://clinicaltrials.gov/show/NCT01949337. NLM identifier: CT01949337Accessed December 10, 2013
   Google Scholar
• Aragon Pharmaceuticals IncSafety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate Available from: http://clinicaltrials.gov/show/NCT01792687. NLM identifier: NCT01792687Accessed December 10, 2013
   Google Scholar
• M.D. Anderson Cancer CenterAbiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide Available from: http://clinicaltrials.gov/show/NCT01946165. NLM identifier: NCT01946165Accessed December 10, 2013
   Google Scholar
• Medical Research CouncilSTAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled Trial Available from: http://clinicaltrials.gov/show/NCT00268476. NLM identifier: NCT00268476Accessed December 10, 2013
   Google Scholar
• Janssen Research & Development LLCA Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Patients With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC) Available from: http://clinicaltrials.gov/show/NCT01715285. NLM identifier: NCT01715285Accessed December 10, 2013
   Google Scholar
• UNICANCERSafety and Efficacy of Radiotherapy Combined With a 6-month LH-RH Agonist and Abiraterone Hormone Therapy Treatment in Biochemically-relapsing Prostate Cancer Following Surgery (CARLHA) Available from: http://clinicaltrials.gov/show/NCT01780220. NLM identifier: NCT01780220Accessed December 10, 2013
   Google Scholar
• University of WashingtonAbiraterone Acetate, Prednisone, and Leuprolide Acetate or Goserelin Before and During Radiation Therapy in Treating Patients With Localized or Locally Advanced Prostate Cancer Available from: http://clinicaltrials.gov/show/NCT01023061. NLM identifier: NCT01023061Accessed December 10, 2013
   Google Scholar
• Duke UniversityAbiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer Available from: http://clinicaltrials.gov/show/NCT01717053. NLM identifier: NCT01717053Accessed December 10, 2013
   Google Scholar
• Memorial Sloan-Kettering Cancer Center3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy Available from: http://clinicaltrials.gov/show/NCT01751451. NLM identifier: NCT01751451Accessed December 10, 2013
   Google Scholar
• MostaghelEANelsonPSLangePTargeted androgen pathway suppression in localized prostate cancer: a randomized clinical trialJ Clin OncolEpub 2013129
   Google Scholar
• TaplinMEMontgomeryRBLogothetisCEffect of neoadjuvant abiraterone acetate (AA) plus leuprolide acetate (LHRHa) on PSA, pathological complete response (pCR), and near pCR in localized high-risk prostate cancer (LHRPC): results of a randomized Phase II study [abstract]J Clin Oncol201230Suppl4521
   Google Scholar